原发性肝细胞肝癌的TACE联合外科治疗及单纯外科手术治疗对照研究  

Control Study of Surgery Combined with TACE and Simple Surgical Treatment on HCC

作　　者：孙林[1] 成伟[1] 刘觉仕[1] 王俊[1] 向华[1] 

机构地区：[1]湖南省人民医院,湖南长沙410011

出　　处：《医学与哲学（B）》2012年第11期16-18,共3页Medicine & Philosophy(B)

摘　　要：对比单纯外科治疗以及外科手术联合TACE治疗原发性肝癌的疗效以及生存时间。回顾性分析我院2006年至2009年的260例原发性肝癌的治疗情况,分为单纯外科组(对照组)以及TACE联合外科手术组进行对照研究,比较术后3月的疾病控制率;并比较其1,2,3年生存率,以kaplan—Meier生存曲线进行生存分析。结果3个月时疾病控制率单纯手术组为75.70%,TACE联合手术组为85.62%,P=0.043有统计学差异。单纯手术组第1、2、3年生存率为55.14%,15.89%,9.35%;TACE联合手术组为66.01%,27.45%,18.95%,第1年生存率两者没有统计学差异,P=0.076;第2、3年生存率联合组明显高于单纯手术组,P=0.029,P=0.033。因此,TACE联合外科手术治疗原发性肝细胞肝癌的远期疗效比单纯手术有明显优势。To compare effects and life cycle of simple surgical treatment and surgery combined with trans--catheter arterial chemo--embolization （TACE） on patients with advanced un--resectable hepatocellular carcinoma （HCC）. Clinical data of 260 consecutive patients who underwent hepatectomy for HCC in our hospital from 2006 to 2009 were analyzed retrospec- tively. According to the different treatment modalities, these patients have been divided into simple surgical group （ control group） and group of surgery combined with TACE （combined group） to proceed controlled studies and to compare the Disease Control Rate （ DCR） three months after patients＇operation, to compare 3 year survival rates and analyzed using Kaplan--Meier survival curves. For control group and combined group, the 3--month DCR were 75.70 % and 85.62 %respec- tively （P=0. 043） there was a statistically difference. For control group, 1, 2 and 3 year survival rates were 55.14%, 15.89%, 9.35% respectively; for combined group, the rates were 66.01%, 27.45%, 18.95% accordingly. There was no significant differences for 1 year survival rates （P= 0. 076）, but 2 and 3 year survival rates of combined group were ap- parently higher than control group （P = 0. 029, P： 0. 033）. The long--term effect of surgery combined with TACE on patients with advanced un--resectable HCC has a distinct advantage over those of simple surgical treatment.

关 键 词：原发性肝癌 外科手术切除 肝动脉栓塞化疗 

分 类 号：R735.7[医药卫生—肿瘤]